Biosynex SA (EPA:ALBIO)

Market Cap	23.06M
Revenue (ttm)	101.17M
Net Income (ttm)	-43.33M
Shares Out	18.75M
EPS (ttm)	-4.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,004
Average Volume	58,106
Open	1.230
Previous Close	1.230
Day's Range	1.165 - 1.250
52-Week Range	0.991 - 5.710
Beta	0.36
RSI	42.49
Earnings Date	Jul 17, 2025

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1993
• Employees: 476
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.